pgm169/gl67a
Gene therapyexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00789867)
Timeline
Indications
Studied for
Mechanism of action
- Cystic fibrosis transmembrane conductance regulatorSupplementation
CFTR supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pgm169/gl67a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01621867 | Phase 2 | May 1, 2012 | University of Edinburgh, University of London, University of Oxford |
| NCT00789867 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2008 | Cystic Fibrosis Trust, University of Edinburgh, University of London, University of Oxford, University of Pennsylvania |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Edinburgh | Academic/Hospital | 2 | 0 | 1 | 2008 |
| University of London | Academic/Hospital | 2 | 2 | 1 | 2008 |
| University of Oxford | Academic/Hospital | 2 | 0 | 1 | 2008 |
| Cystic Fibrosis Trust | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2008 |
5 organizations
Page 1 / 1